Abundance evidences demonstrate that TAK1 is a vital upstream activator of the MAPK signaling pathway and participates in the development of NAFLD, and its activation was fine-tuned by ubiquitination (19, 32, 33). The gene discussed is MAP3K7; the disease is metabolic dysfunction-associated steatotic liver disease.